Nodelman Oleg's Form 4 filing
Aktis Oncology, Inc. (AKTS) · filed Jan 12, 2026
- Accession no.
- 0000935836-26-000031
- Filed
- Jan 12, 2026, 8:28 PM ET
- Trade date
- Jan 12, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 5 non-derivative transactions and 7 derivative transactions. Open-market purchases total $40.0M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Nodelman OlegCIK 0001454385 | Director |
| EcoR1 Capital, LLCCIK 0001587114 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 12, 2026 | Common Stock | CConversionAcquired | +2,270,879 | –F1 | – | 2,270,879 | Indirect | |
| Jan 12, 2026 | Common Stock | CConversionAcquired | +202,862 | –F1 | – | 202,862 | Indirect | |
| Jan 12, 2026 | Common Stock | CConversionAcquired | +128,506 | –F1 | – | 128,506 | Indirect | |
| Jan 12, 2026 | Common Stock | PPurchaseAcquired | +2,077,779 | $18.00 | +$37,400,022 | 4,348,658 | Indirect | |
| Jan 12, 2026 | Common Stock | PPurchaseAcquired | +144,443 | $18.00 | +$2,599,974 | 347,305 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 12, 2026 | Common Stock | CConversionDisposed | −2,605,878 | –F1 | – | 0 | Indirect | |
| Jan 12, 2026 | Common Stock | CConversionDisposed | −262,142 | –F1 | – | 0 | Indirect | |
| Jan 12, 2026 | Common Stock | CConversionDisposed | −128,506 | –F1 | – | 0 | Indirect | |
| Jan 12, 2026 | Common Stock | CConversionDisposed | −630,191 | –F1 | – | 0 | Indirect | |
| Jan 12, 2026 | Common Stock | CConversionDisposed | −26,942 | –F1 | – | 0 | Indirect | |
| Jan 12, 2026 | Common Stock | CConversionAcquired | +965,190 | –F1 | – | 965,190 | Indirect | |
| Jan 12, 2026 | Common Stock | CConversionAcquired | +86,222 | –F1 | – | 86,222 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date.
Referenced by the price of 3 transactions in Table I and 7 transactions in Table II.
Remarks
EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund, Capital Fund and Venture Fund. Mr. Nodelman is a director of the Issuer and is the manager and controlling owner of EcoR1. The reporting persons are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The reporting persons disclaim beneficial ownership of the securities reported herein, except to the extent of their respective pecuniary interests therein.